Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
TLX250-CDx's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for TLX250-CDx. Showing past 6 months and next 12 months · 9 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| TLX250-CDx | Telix Pharmaceuticals | Diagnostic Device | Phase 3 | 0 | ||||
| 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Telix Pharmaceuticals (Innovations) Pty Limited | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| CD70-targeted immunoPET Imaging of Kidney Cancer | RenJi Hospital | — | Phase 2 | — | — | — | — | — |
| Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | Peking Union Medical College Hospital | — | Phase 2 | — | — | — | — | — |
| CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC | Massachusetts General Hospital | — | Phase 2 | — | — | — | — | — |
| Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation | john eisenbrey | — | Phase 2 | — | — | — | — | — |
| Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | UNC Lineberger Comprehensive Cancer Center | — | Phase 2 | — | — | — | — | — |
| 64Cu-GRIP B in Patients With Advanced Malignancies | Rahul Aggarwal | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | ITM Oncologics GmbH | — | PHASE1/PHASE2 | — | — | — | — | — |